Analyzing Pharming Group (PHGUF) and Turning Point Brands (TPB)

Pharming Group (OTCMKTS: PHGUF) and Turning Point Brands (NYSE:TPB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Valuation and Earnings

This table compares Pharming Group and Turning Point Brands’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pharming Group $101.29 million 10.29 -$90.37 million N/A N/A
Turning Point Brands $285.78 million 1.55 $20.20 million $1.08 21.33

Turning Point Brands has higher revenue and earnings than Pharming Group.

Profitability

This table compares Pharming Group and Turning Point Brands’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pharming Group -69.48% -259.69% -33.75%
Turning Point Brands 7.29% 54.27% 9.14%

Volatility & Risk

Pharming Group has a beta of 3.25, meaning that its stock price is 225% more volatile than the S&P 500. Comparatively, Turning Point Brands has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Pharming Group and Turning Point Brands, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group 0 0 2 0 3.00
Turning Point Brands 0 0 3 0 3.00

Turning Point Brands has a consensus target price of $22.33, suggesting a potential downside of 3.07%. Given Turning Point Brands’ higher probable upside, analysts plainly believe Turning Point Brands is more favorable than Pharming Group.

Dividends

Turning Point Brands pays an annual dividend of $0.16 per share and has a dividend yield of 0.7%. Pharming Group does not pay a dividend. Turning Point Brands pays out 14.8% of its earnings in the form of a dividend.

Institutional and Insider Ownership

20.1% of Turning Point Brands shares are held by institutional investors. 6.9% of Turning Point Brands shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Turning Point Brands beats Pharming Group on 10 of the 13 factors compared between the two stocks.

Pharming Group Company Profile

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein. It also engages in the development of recombinant human C1 inhibitor for treating HAE attacks; and recombinant human factor VIII (rhFVIII), a natural human blood clotting factor for treating haemophilia A. The company has a strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture, and commercialization of new products based on the Pharming technology platform; and a partnership agreement with the China State Institute of Pharmaceutical Industry for the development of rhFVIII for the treatment of Haemophilia A. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Turning Point Brands Company Profile

Turning Point Brands, Inc., together with its subsidiaries, provides other tobacco products primarily in the United States. It operates through three segments: Smokeless Products, Smoking Products, and NewGen Products. The Smokeless Products segment manufactures and markets moist snuff; and contracts for and markets loose leaf chewing tobacco products. The Smoking Products segment imports and markets cigarette papers, tubes, and related products, as well as finished cigars, make-your-own cigar tobaccos, and cigar wraps; and processes, packages, and markets pipe tobaccos. The NewGen Products segment markets and distributes liquid vapor products, tobacco vaporizer products, and other products without tobacco and nicotine, including e-cigarettes, e-liquids, vaporizers, and other related products; and distributes various assortments of vaping products to non-traditional retail outlets through VaporBeast and Vapor Shark, as well as distributes various vaping related products to individual consumers through Vapor Shark branded retail outlets. The company sells its products under the Zig-Zag, Beech-Nut, Stoker's, Trophy, Havana Blossom, Durango, Our Pride, Big Mountain, Appalachia, Springfield Standard, Snake River, Tequila Sunrise, Fred's Choice, Old Hillside, Red Cap, Tennessee Chew, VaporBeast, and Vapor Shark brands. It sells its products to wholesale distributors and retail merchants in the independent and chain convenience store, tobacco outlet, food store, mass merchandising, and drug store and non-traditional retail channels. The company was formerly known as North Atlantic Holding Company, Inc. and changed its name to Turning Point Brands, Inc. in November 2015. Turning Point Brands, Inc. was incorporated in 2004 and is headquartered in Louisville, Kentucky.

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply